SciSparc Ltd. (NASDAQ:SPRC) Short Interest Up 5,157.1% in May

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 378,196 shares, an increase of 5,157.1% from the May 14th total of 7,194 shares. Currently, 67.9% of the shares of the stock are sold short. Based on an average trading volume of 3,858,258 shares, the short-interest ratio is currently 0.1 days.

SciSparc Trading Down 10.7%

Shares of SciSparc stock traded down $1.11 during trading on Tuesday, hitting $9.31. 67,343 shares of the company were exchanged, compared to its average volume of 711,963. SciSparc has a fifty-two week low of $2.98 and a fifty-two week high of $80.10. The firm has a 50 day moving average price of $5.82 and a 200 day moving average price of $8.64.

SciSparc (NASDAQ:SPRC) last issued its quarterly earnings data on Wednesday, April 29th. The company reported ($31.60) earnings per share (EPS) for the quarter. The company had revenue of $0.20 million during the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of SciSparc in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About SciSparc

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.